What is NextGen Jane?
NextGen Jane operates as a pioneering biotechnology firm dedicated to the longitudinal molecular study of women's health. By empowering a community of menstruators to contribute biological data through a specialized collection kit, the company is effectively mapping the complexities of uterine biology. This data-driven model allows for the identification of early indicators of disease, offering a transformative approach to diagnostics that was previously inaccessible. The company's market position is defined by its ability to bridge the gap between consumer-facing health engagement and rigorous genomic research, creating a unique value proposition in the broader healthcare landscape.
How much funding has NextGen Jane raised?
NextGen Jane has raised a total of $11.3M across 2 funding rounds:
Angel/Seed
$2.3M
Series A
$9M
Angel/Seed (2019): $2.3M with participation from Undisclosed
Series A (2019): $9M led by Viking Global Investors, Material Impact, Access Industries, and Liminal Ventures
Key Investors in NextGen Jane
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
Material Impact
Material Impact is focused on building deep tech companies that leverage material science to drive innovation, supporting founders to create impactful solutions that enhance productivity and sustainability.
Access Industries
Access Industries is a privately-held industrial conglomerate that makes strategic investments globally, maintaining a diversified portfolio across sectors including biotechnology and venture capital.
What's next for NextGen Jane?
With the recent capital infusion, NextGen Jane is poised to accelerate its research and development initiatives, focusing on the refinement of its molecular diagnostic tools. The strategic backing from high-profile investors suggests a long-term commitment to scaling the company's platform, likely involving the expansion of its clinical partnerships and the enhancement of its data processing capabilities. As the firm continues to unlock insights from menstrual blood, the focus will shift toward integrating these findings into clinical workflows, ultimately aiming to redefine standard treatment options for gynecological conditions. The company remains a critical player to watch as it navigates the intersection of deep tech and personalized medicine.
See full NextGen Jane company page
